Shots:

• Aclaris to receive $55M in cash including $35M up front and sales milestones of up to $20M apart from is eligible for royalties on sales of product-by-product and country-by-country basis plus 25% of any up front- license- milestone- maintenance or fixed payment received by EPI from a licensee or sublicensee in any territory outside of the US   
• EPI Health to get Aclaris’ Rhofade with all its intellectual property and WW rights including the assignment of certain licenses for related intellectual property assets. The focus of the diversion is to refocus on the resources to develop immuno-inflammatory portfolio
• Rhofade is an alpha1A adrenoceptor agonist indicated for topical treatment of persistent facial erythema associated with rosacea in adults

Click here to­ read full press release/ article | Ref: Aclaris Therapeutics| Image: Twitter